Perrigo Executives Stage Coordinated Buying Spree Amid Stock Dip, Hinting at Strategic Upside

Insider Activity Highlights a Shift in Confidence

On March 6, 2026, Willis Robert, the EVP and CHRO of Perrigo Co PLC, completed a series of ordinary‑share transactions that, taken together, reveal a nuanced view of the company’s current trajectory. Robert purchased 2,743 shares and 8,019 shares, while selling 1,430, 916, 4,178, and 2,742 restricted‑stock units (RSUs). These trades net a modest increase in his shareholdings to 52,113 shares, implying a belief that the stock will rebound from its recent trough at €8.86—its 52‑week low—and potentially benefit from the company’s strategic repositioning in the OTC and generic pharmaceuticals space.

Market‑Wide Insider Moves Amplify the Narrative

The March 6 filing was not an isolated event. Across the board, CEOs, CFOs, and other executives performed a flurry of buys and sells at the same price point of €10.72, reflecting the company’s share price on the day. Patrick Lockwood‑Taylor, the CEO, bought 11,727 shares and sold 4,240, while Bezerra Guarita, the CFO, added and off‑loaded shares in a similar pattern. These synchronized transactions suggest a coordinated assessment of the company’s valuation: a short‑term dip but a long‑term upside, especially as Perrigo continues to focus on high‑margin OTC products amid tightening generic competition.

Implications for Investors

For investors, Robert’s net buying, coupled with the broader insider buying spree, signals that senior management maintains a positive outlook despite the steep decline in market price and the low price‑to‑earnings ratio of 7.13. The recent press release announcing participation in the UBS Global Consumer and Retail Conference could hint at upcoming product launches or strategic partnerships that may lift demand. However, the current 66 % drop from the all‑time high and the below‑book valuation (P/B = 0.48) raise cautionary flags. A prudent approach would be to monitor earnings guidance and any regulatory developments, while considering a buy‑low strategy if the company’s cash flow stability and product pipeline can justify a valuation reset.

Looking Ahead

Perrigo’s future hinges on its ability to leverage its OTC and generic drug segments while navigating a highly competitive health‑care market. The insider transactions imply confidence in a turnaround, yet the market’s continued skepticism—evidenced by the stock’s steep weekly drop of 10.55%—demands vigilance. Investors should weigh the insider sentiment (+33 on social media) against the broader market buzz (223 % buzz indicates heightened discussion but not necessarily positive consensus). In sum, while the insiders’ actions provide a bullish signal, the company’s valuation and recent performance metrics warrant a cautious yet opportunistic stance for forward‑looking investors.